Human Fecal Mucin Glycosylation as a New Biomarker in Inflammatory Bowel Diseases. - Université de Lille Accéder directement au contenu
Article Dans Une Revue Inflammatory Bowel Diseases Année : 2022

Human Fecal Mucin Glycosylation as a New Biomarker in Inflammatory Bowel Diseases.

Résumé

For the first time, fecal mucins of Crohn’s disease patients were analyzed by mass spectrometry. Compared with control subjects, Crohn’s disease patients showed a significant decrease in sialylated glycans that we propose as new noninvasive tool for screening of intestinal diseases.
Fichier principal
Vignette du fichier
izac244.pdf (1.17 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04480048 , version 1 (27-02-2024)

Licence

Identifiants

Citer

Catherine Masselot, Camille Cordier, Benjamin Marsac, Maria Nachury, Renaud Leonard, et al.. Human Fecal Mucin Glycosylation as a New Biomarker in Inflammatory Bowel Diseases.. Inflammatory Bowel Diseases, 2022, Inflammatory Bowel Diseases, 29, pp.167-171. ⟨10.1093/ibd/izac244⟩. ⟨hal-04480048⟩
15 Consultations
2 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More